Brookline analyst Leah Rush Cann downgraded MEI Pharma to Hold from Buy without a price target after the company announced it is exploring strategic alternatives. The firm says extending its current cash runway beyond December 31 hinges on the cost saving and the strategic directions MEI pursues. The analyst cites increased uncertainty to the path forward for the downgrade.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks